Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sendai
Clinical trial register · Japan

Clinical Trials in Sendai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer18 Merck Sharp & Dohme LLC17 AbbVie16 Novartis Pharmaceuticals13 Bristol-Myers Squibb10
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Sendai

204 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Kiminori Kimura, MD
Phase 2
7
Sapporo, Sendai, Osaka, Bunkyo-Ku
2026-10-01
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Toon-Shi, Kurume-Shi, Yokohama, Sendai, Okayama, Hirakata-Shi, Osakasayama-Shi
2026-09-08
Not yet open
Breakthrough Platform Trial for PCAS
NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
630
Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama
2026-09-01
Recruiting
Eli Lilly and Company
Phase 2
606
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Kobe, Sendai
2026-06-18
Recruiting
Astellas Pharma Inc
Phase 1/2
84
Sendai, Bunkyo-ku, Toyama, Kyoto, Tokushima
2026-04-03
Recruiting
Eisai Co., Ltd.
Phase 2
256
Nagoya, Toyoake, Kitakyushu, Sapporo, Kobe, Nishinomiya, Sendai, Naha
2026-03-31
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Eli Lilly and Company
Phase 3
300
Ichikawa, Iruma, Moriyama, Osaka, Sendai, Shizuoka
2026-02-05
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Kashiwa, Sendai, Hirakata, Nagaizumi-cho, Bunkyo-ku
2026-01-30
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Recruiting
argenx
Observational
70
Tsukuba, Kawasaki-Shi, Sendai, Hanamaki, Narita
2025-12-19
Recruiting
argenx
Phase 2
70
Tsukuba, Kawasaki-shi, Sendai, Hanamaki, Narita
2025-12-19
Recruiting
AbbVie
Phase 2
100
Nagoya, Kashiwa-shi, Fukuoka, Sapporo, Kyoto, Sendai, Okayama, Chuo-Ku
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Kurume, Asahikawa, Sapporo, Yokohama, Sendai, Matsumoto, Ōmura, Kashihara
2025-11-30
Recruiting
Genmab
Phase 3
660
Chiba, Ōta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka
2025-11-28
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
14
Nagoya, Fukuoka, Hiroshima, Sapporo, Kyoto, Sendai, Niigata, Ōsaka-sayama
2025-11-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Nagoya, Kashiwa, Tōon, Kurume, Sapporo, Nishinomiya, Yokohama, Sendai
2025-11-05
Recruiting
Bristol-Myers Squibb
Observational
223
Sendai, Toyama, Kitakyushu-Shi, Wakayama
2025-10-08
Recruiting
Kazuya Hosokawa
Phase 4
36
Fukuoka, Kobe, Kyoto, Nagoya, Okayama, Sendai, Tokyo
2025-10-07
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Chiba, Fuchū, Niigata, Sagamihara, Sanda-shi, Sendai
2025-09-30
Recruiting
Pfizer
Phase 3
680
Kurume, Kure, Akashi, Kochi, Tsu, Sendai, Ōmura, Beppu-shi
2025-09-29
Recruiting
Pfizer
Phase 3
140
Sendai, Niigata, Osaka, Hamamatsu, Mitaka
2025-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
182
Kashiwa, Sendai, Hirakata
2025-09-09
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
Pfizer
Phase 3
6,000
Kurume, Sendai, Beppu-shi, Habikino, Izumisano, Kofu, Fukui, Kyoto
2025-08-25
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
Pfizer
Phase 3
208
Sendai, Niigata, Hamamatsu, Mitaka, Osaka
2025-07-31
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka
2025-07-16
Active, closed
AbbVie
Phase 3
125
Nagoya, Kurume-shi, Kahoku-gun, Ebina-shi, Miyagi-gun, Sendai, Niigata, Osaka
2025-06-19
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
Osaka, Sendai, Tokyo
2025-06-10
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Kashiwa, Sakura, Chikushino-shi, Maebashi, Shiwa-gun, Yokohama, Tsu, Sendai
2025-05-27
Recruiting
Aveir Leadless Pacemaker Japan PMS
NCT07106788Leadless Pacemaker
Abbott Medical Devices
Observational
304
Nagoya, Kitakyushu, Kawasaki, Sendai, Kurashiki, Hirakata, Osaka, Suita
2025-05-26
Recruiting
Takeda
Phase 3
59
Nagoya, Kumamoto, Sendai, Kashihara, Higashi-Matsuyama, Ōtsu, Tokushima, Bunkyo-ku
2025-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Nagoya, Sapporo, Kanazawa, Sagamihara, Yokohama, Sendai, Kashihara, Kurashiki
2025-04-24
Recruiting
AbbVie
Phase 2
390
Nagoya, Kashiwa-shi, Kawasaki-shi, Sendai, Chuo-Ku
2025-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Nagoya, Toyoake, Sapporo, Sendai, Hirakata, Izumo, Bunkyo, Chūō
2025-04-11
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Kamakura-shi, Sendai, Kurashiki-shi, Saitama, Fuchu-shi, Fukuoka-ken, Kanagawa, Kawasaki
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Asahikawa-shi, Takamatsu, Sendai, Aichi, Aomori, Chiba, Chikushino-shi, Ehime
2025-03-17
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
DrugsIBI305·HD204·Bevacizumab-awwb·BP102
NRG Oncology
Phase 3
880
Sendai, Tōon, Kure, Sapporo, Akashi, Shiwa-gun, Kagoshima, Gunma
2025-03-12
Recruiting
Pfizer
Phase 3
723
Kobe, Kyoto-shi Shimogyo-ku, Sendai, Shibuya-ku, Kai, Kagoshima
2025-03-11
Active, closed
Takeda
Phase 3
601
Minami-ku, Nagoya-shi, Nagoya, Sapporo, Fukuoka, Ono-shi, Tsu, Mie, Sendai, Sasebo-shi
2025-03-10
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Matsuyama, Kurume, Sapporo, Kobe, Kanazawa, Yokohama, Sendai, Kashihara
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Kitakyushu, Kamakura, Yokohama, Sendai, Itabashi-ku
2025-02-24
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Fukuoka, Itabashi Ku, Kita Gun, Nagoya, Osaka, Ōita, Sasebo, Sendai
2025-02-21
Active, closed
AbbVie
Phase 3
468
Kobe, Kawasaki-shi, Kochi, Sendai, Ōita, Osaka, Setagaya-ku, Shibuya-ku
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Sapporo, Nishinomiya, Hanamaki, Sendai, Suita, Higashi-Matsuyama, Koshigaya, Shinjuku Ku
2025-02-07
Active, closed
Genmab
Phase 3
584
Nagoya, Kurume, Sapporo, Kawasaki, Sendai, Niigata, Okayama, Hidaka
2025-02-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai
2025-01-27
Recruiting
AbbVie
Phase 2
150
Nagoya, Kashiwa-shi, Sapporo, Kobe, Sagamihara-shi, Sendai, Miyazaki, Kurashiki-shi
2025-01-20
Active, closed
Pfizer
Phase 3
1,035
Nagoya, Otashi, Sapporo, Yokohama, Sakyo-ku, Sendai, Suita, Bunkyo-ku
2025-01-06
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Kawachi-Nagano, Sakai, Suita, Hamamatsu
2024-12-09
Active, closed
H. Lundbeck A/S
Phase 3
401
Nagoya, Toyoake-Shi, Gifu, Sapporo, Sendai, Niigata, Iruma-shi, Bunkyō City
2024-12-03
Active, closed
Verastem, Inc.
Phase 2
16
Nagoya, Kurume, Tsu, Sendai, Minato
2024-10-30
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sapporo, Sendai, Suita, Bunkyo-ku, Fukuoka, Ishikawa, Kyoto
2024-10-29
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
Chiba, Fuchū, Gifu, Niigata, Sagamihara, Sanda-shi, Sendai
2024-10-02
Active, closed
Merus B.V.
Phase 3
699
Nagoya, Kashiwa, Fukuoka, Hiragi, Natori-shi, Sendai, Ōsaka-sayama, Chuo Ku
2024-09-25
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
Nagara, Nishinomiya, Sendai, Toyonaka, Kodaira
2024-09-18
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku
2024-09-04
Recruiting
Bayer
Phase 3
444
Nagoya, Kashiwa, Sapporo, Himeji, Kobe, Sagamihara, Sendai, Hirakata
2024-08-28
Recruiting
Colorado Prevention Center
Phase 3
2,600
Sapporo, Isehara, Sagamihara, Kyoto, Sendai, Osaka, Suita, Ōta-ku
2024-08-20
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Sakai, Suita, Hamamatsu, Bunkyō-Ku
2024-08-19
Active, closed
AbbVie
Phase 3
111
Kashiwa-shi, Kurume-shi, Sendai, Izumi-Shi, Saga, Saitama-shi, Bunkyo-ku, Fuchu-shi
2024-08-08
Active, closed
Pfizer
Observational
450
Kitakyushu-shi, Kurume-shi, Ebina, Sendai, Niigata, Osaka, Hamamatsu, Bunkyo-ku
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Kitakyushu, Naka, Ushiku, Kanazawa, Morioka, Sendai, Izumisano, Kashihara
2024-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Chiba, Narita, Sapporo, Nishinomiya, Hanamaki, Sendai, Suita, Higashi-Matsuyama
2024-07-31
Active, closed
Vor Biopharma
Phase 3
191
Nagoya, Sapporo, Kobe, Kawasaki, Yokohama, Sendai, Kashiwazaki-Shi, Ginowan-Shi
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Active, closed
Merus B.V.
Phase 3
621
Chūōku, Fukuoka, Kashiwa, Miki, Nagoya, Natori, Ōsaka-sayama, Sendai
2024-06-25
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Active, closed
Takeda
Phase 1/2
28
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Shiwa-gun, Sendai
2024-05-20
Active, closed
Sanofi
Phase 3
1,541
Chitose, Obihiro, Sapporo, Kobe, Sagamihara, Yokohama, Miyagi-gun, Sendai
2024-05-08
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Chiba, Morioka, Sagamihara-shi, Kyoto, Sendai, Moriguchi-shi, Osaka, Kawagoe-shi
2024-04-16
Recruiting
Eli Lilly and Company
Phase 3
90
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya Ku, Tokyo
2024-03-13
Recruiting
Takeda
Phase 2
268
Sapporo, Nishinomiya, Morioka, Sendai, Hirakata, Takatsuki-shi, Hamamatsu, Minato
2024-03-05
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Active, closed
Janssen Pharmaceutical K.K.
Phase 3
19
Hokkaido, Ichinomiya, Itabashi Ku, Kitakyushu-shi, Kumamoto, Nagoya, Osaka, Sendai
2024-02-09
Active, closed
Incyte Corporation
Phase 3
617
Ginowan-shi, Itabashi-ku, Kurume-shi, Kyoto, Niigata, Sapporo, Sendai, Shinjuku-ku
2024-01-30
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
Active, closed
Pfizer
Phase 3
394
Nagoya, Sendai, Sakai, Bunkyo-ku, Shinjuku-ku, Kofu
2024-01-19
Active, closed
Pfizer
Phase 2
333
Otashi, Sendai, Suita, Chuo-ku, Chiba, Hiroshima, Osaka
2024-01-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Toyoake, Kashiwa, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai
2023-12-31
Active, closed
Bristol-Myers Squibb
Phase 3
190
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sendai, Bunkyo Ku, Yonago
2023-12-21
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Chuo-ku, Chiba-shi, Kitakyushu, Sapporo, Sagamihara, Yokohama, Sendai, Habikino, Kawagoe
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Fukuoka, Gifu, Izumi-shi, Ōta-ku, Sendai
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nagoya, Hirosaki-Shi, Fukuoka, Sagamihara, Yokohama, Kumamoto, Sendai, Okayama
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Maebashi, Sapporo, Kobe, Sendai, Sakai, Izumo, Koto
2023-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Active, closed
AstraZeneca
Phase 3
760
Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Mitaka-shi, Nagoya, Osaka, Sendai
2023-12-04
Active, closed
AbbVie
Observational
250
Matsuyama, Asahikawa, Hakodate-shi, Ryūgasaki, Tsukuba, Kagoshima, Kyoto, Sendai
2023-11-30
By invitation
Shanghai Henlius Biotech
Phase 1
367
Sendai, Sayama, Matsuyama, Okayama, Shizuoka, Tokyo
2023-11-24
Active, closed
BeOne Medicines
Phase 3
652
Nagoya, Chiba, Matsuyama, Sapporo, AmagasakiCity, Kagoshima, Iseharashi, Sendai
2023-11-11
Active, closed
AbbVie
Phase 3
122
Kashiwa-shi, Kurume-shi, Sapporo, Sendai, Izumi-Shi, Osaka, Saitama-shi, Bunkyo-ku
2023-11-06
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Recruiting
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients
NCT06014801Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
Jikei University School of Medicine
Phase 2/3
400
Sendai, Takatsuki, Fukui, Ibaraki, Osaka, Tochigi, Tokyo, Wakayama
2023-10-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
19
Nagoya, Sapporo, Yokohama, Sendai, Matsumoto, Niigata, Hidaka, Izumo
2023-10-20
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Itabashi Ku, Kitakyushu-shi, Mito, Nagoya, Osaka Sayama Shi, Sendai, Shinjuku, Tsu
2023-10-12
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
92
Toyoake, Kyoto, Sendai, Toyonaka, Fuchū
2023-09-22
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Sapporo, Kobe, Yokohama, Sendai, Matsumoto, Mitaka, Gifu
2023-08-22
Active, closed
AstraZeneca
Phase 3
142
Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama
2023-08-16
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
16
Chikushino-shi, Sendai, Nishihara, Suita, Bunkyo-ku, Minato-ku, Shinjuku-ku, Asahikawa
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Nagoya, Kashiwa-shi, Fukuoka, Sendai, Niigata, Sayama, Sunto-gun, Chuo Ku
2023-07-31
Active, closed
AbbVie
Phase 3
1,014
Kitakyushu-shi, Sapporo, Sendai, Miyazaki, Okayama, Naha, Kawagoe, Bunkyo-ku
2023-07-25
By invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 4
59
Sendai, Kyoto, Ōta-ku
2023-07-06
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Sendai, Kashiwa-Shi, Nagasaki, Nagoya, Osaka-Fu
2023-07-05
Active, closed
AbbVie
Phase 3
1,328
Fukuoka, Nishinomiya-shi, Tsukuba, Kyoto, Sendai, Ginowan-shi, Sakai-shi, Ōtsu
2023-06-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
39
Toyoake, Kurume, Otashi, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-06-13
By invitation
AbbVie
Phase 3
650
Kobe, Nishinomiya-shi, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-06-05
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Kurume, Akashi, Hirakata, Kashiwa, Nagoya, Ōsaka-sayama, Sapporo, Sendai
2023-06-01
Active, closed
Amgen
Phase 3
509
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yokohama, Sendai
2023-05-31
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Recruiting
AbbVie
Phase 3
450
Kobe, Nishinomiya, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-05-01
Active, closed
Multi-omics Study in Citrin Deficiency
NCT06895746Citrin Deficiency
Johannes Haeberle
Observational
100
Kurume-shi, Saitama, Yokohama, Tokyo, Sendai, Matsumoto, Hokkaido, Osaka
2023-04-01
Recruiting
National Cancer Center, Japan
Phase 2
32
Kashiwa, Sapporo, Kyoto, Sendai, Chuo-ku, Fukuoka
2023-03-29
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Recruiting
Lantern Pharma Inc.
Phase 2
90
Sapporo, Yokohama, Sendai, Okayama, Chuo-ku
2023-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Toyoake, Kurume, Ōta, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-02-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Nagoya, Matsuyama, Kurume, Takarazuka, Kanazawa, Yokohama, Natori-shi, Sendai
2023-02-06
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
45
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Kitakyushu-shi, Sapporo, Amagasaki, Sagamihara, Sendai, Shinagawa-ku, Osaka
2022-12-14
Active, closed
Kringle Pharma, Inc.
Phase 3
62
Toyoake, Fukuoka, Kurume, Kamigyō-ku, Sendai, Kurashiki, Chiyoda-ku, Minato-Ku
2022-12-01
Recruiting
Pfizer
Phase 3
1,060
Yoshida-gun, Maebashi, Yahaba-cho, Sendai, Nagaizumi-cho, Shibuya-ku, Fukuoka, Okayama
2022-11-10
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Active, closed
Janssen Research & Development, LLC
Phase 2
36
Fukuoka, Fukushima, Kanagawa, Kawachi-Nagano, Matsudo-shi, Matsumoto, Sendai, Tokyo
2022-07-05
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Itabashi-ku, Kumamoto, Mitaka, Miyazaki, Sendai, Tsu
2022-06-30
Recruiting
Astellas Pharma Inc
Phase 1
681
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata
2022-06-08
Active, closed
Sanofi
Phase 3
104
Sapporo, Kagoshima, Kawasaki, Sendai, Fukuoka, Tokyo
2022-05-03
Active, closed
Sanofi
Phase 3
43
Odawara, Sendai
2022-04-18
Active, closed
Pfizer
Phase 3
854
Nagoya, Maebashi, Kobe, Yahaba-cho, Kyoto, Sendai, Hamamatsu, Sunto-gun
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai
2022-03-24
Active, closed
AstraZeneca
Phase 3
1,051
Himeji-shi, Hiroshima, Kashiwa, Kurume-shi, Natori-shi, Niigata, Osaka, Sendai
2022-02-07
Active, closed
UCB Biopharma SRL
Phase 3
113
Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi
2022-02-02
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Fukuoka, Kyoto, Okayama, Sapporo Hokkaido, Sendai, Tokyo
2021-12-15
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke
2021-12-10
Active, closed
H. Lundbeck A/S
Phase 2
64
Toyoake, Gifu, Sendai
2021-11-16
Recruiting
ModernaTX, Inc.
Phase 1/2
50
Toyoake-shi, Sendai
2021-11-09
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Bunkyō City, Gunma, Ikoma, Kurume, Saitama Shi, Sendai, Setagaya Ku, Tsu
2021-10-18
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872Aortic Stenosis, Calcific, Aortic Valve Stenosis
Edwards Lifesciences
Not applicable
2,250
Fukuoka, Sendai, Fuchū, Shinjuku
2021-10-12
Active, closed
Beeline Medicines Corporation
Phase 2
248
Chiba, Eiheiji-cho,Yoshida-gun, Kitakyushu, Fukushima, Sapporo, Kanazawa, Sendai, Bunkyo-ku
2021-10-11
Recruiting
Pfizer
Phase 3
893
Nagoya, Yoshida-gun, Shibukawa, Yahaba-cho, Sendai, Sunto-gun, Shibuya-ku, Akita
2021-10-04
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Nagoya, Chiba, Yoshida-Gun, Sapporo, Nankoku, Sendai, Koshigaya, Chūō
2021-09-23
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Kasugai, Toyoake, Toyota, Sapporo, Kawasaki, Yokohama, Kyoto, Sendai
2021-09-20
Active, closed
Bristol-Myers Squibb
Phase 3
338
Nagoya, Kitakyushu, Sapporo, Sendai, Sasebo, Kawagoe, Tokyo
2021-09-15
Active, closed
AstraZeneca
Phase 1/2
212
Kashiwa, Niigata, Sendai, Tokyo
2021-09-14
Active, closed
Pfizer
Phase 3
118
Obu-shi, Kurume-shi, Maebashi, Sendai, Izumi, Takatsuki-shi, Saitama-shi, Shimotsuke
2021-08-12
Active, closed
VectivBio AG
Phase 3
158
Kanagawa, Osaka, Sendai, Tokyo
2021-07-13
Active, closed
Novartis Pharmaceuticals
Phase 2
36
Narita, Kurume, Ohtake, Nishinomiya, Kanazawa, Isehara, Yokohama, Sendai
2021-05-25
Active, closed
Savara Inc.
Phase 3
164
Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka
2021-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Recruiting
ModernaTX, Inc.
Phase 1/2
77
Toyoake-shi, Sendai, Tokyo
2021-04-15
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Nagoya, Sapporo, Kobe, Sendai, Osaka Sayama-shi, Kawagoe, Koto, Hiroshima
2021-04-08
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Nagoya, Ogaki-shi, Sapporo, Kobe, Isehara, Nankoku, Sendai, Osaka Sayama-shi
2021-03-09
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Kashiwa, Tokyo, Matsuyama, Sapporo, Akashi, Chiba, Ariake, Sendai
2021-02-02
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
250
Higashiku, Yokohama, Sendai, Chikusa-ku, Shōwaku, Niigata, Kita-ku, Chuo-ku
2021-01-20
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Kanazawa, Nagoya, Osaka, Sendai, Shibuya City
2020-12-15
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Nagoya, Toon-shi, Fukushima, Akashi, Nishinomiya-Shi, Sagamihara, Sendai, Nagasaki
2020-12-02
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
AstraZeneca
Phase 3
134
Chiba, Hamamatsu, Ichikawa-shi, Kawasaki-shi, Nishinomiya-shi, Osaka, Sendai
2020-07-20
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Toyohashi, Chiba, Kitakyushu, Tsukuba, Kamakura, Sendai, Kurashiki-shi, Meguro-ku
2020-07-07
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Nagoya, Kitakyushu, Sendai, Miyazaki, Mitaka, Shinjuku, tabashi City, Kitakyushu-shi
2020-07-01
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Fukuoka, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo, Sendai, Shibuya City
2020-06-12
Active, closed
Eli Lilly and Company
Phase 3
58
Bunkyō, Chiba, Kagoshima, Sendai, Takatsuki, Yokohama
2020-02-12
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Nagoya, Gifu, Himeji, Tokyo, Kumamoto, Sendai, Okayama, Toyama
2020-01-17
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
AstraZeneca
Phase 3
140
Chiba, Kita-gun, Sagamihara-shi, Sendai, Shinjuku-ku
2019-10-29
Active, closed
Eisai Co., Ltd.
Phase 1/2
125
Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku
2019-09-05
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Fukushima, Iruma-gun, Kanagawa, Kitakyusyu-Shi, Kofu, Ōgaki, Sapporo, Sendai
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Nagoya, Kamogawa, Matsuyama, Ōgaki, Himeji, Hitachi, Sagamihara, Sendai
2019-08-12
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Kashiwa, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Sendai, Tomitake, Kashihara
2019-07-24
Active, closed
National Cancer Center Hospital East
Phase 2
51
Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka
2019-07-02
Active, closed
AbbVie
Phase 1
124
Obu-shi, Kobe, Kagoshima, Kawasaki-shi, Sendai, Niigata, Bunkyo-ku
2019-06-24
Recruiting
Eli Lilly and Company
Phase 3
190
Bunkyō, Chiba, Kagoshima, Kanazawa, Niigata, Saitama-shi, Sendai, Shinjuku-ku
2019-04-05
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Chūōku, Habikino-shi, Kōtoku, Kurume-shi, Osaka, Sendai, Suita-shi
2019-03-22
Active, closed
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
DrugE7386
Eisai Co., Ltd.
Phase 1
70
Nagoya, Kashiwa, Sapporo, Sendai, Nagaizumi-cho, Chuo Ku, Fukuoka, Osaka
2019-03-05
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Tōon, Sapporo, Shiwa-Gun, Sendai, Kawagoe, Kodaira, Shinjuku-ku, Chiba
2018-12-28
Active, closed
AstraZeneca
Phase 2
401
Chūōku, Kanazawa, Kurume-shi,, Matsuyama, Nagoya, Sendai, Sunto-gun, Ube-shi
2018-12-21
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Active, closed
Sanofi
Phase 3
475
Nagoya, Higashiibaraki-gun, Konan-ku, Yokohama-shi, Kumamoto, Sendai, Okayama, Sunto-gun, Shibuya-ku
2017-12-07
Active, closed
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03155191Lymphoblastic Leukemia, Acute Adult
Takara Bio Inc.
Phase 1/2
21
Akita, Yoshida, Higashiku, Sapporo, Kobe, Tsu, Sendai, Okayama
2017-06-01
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
DrugsBleomycin·Cis-platinum·CDDP·Paraplatin
Children's Oncology Group
Phase 3
1,780
Sendai, Chiba-sgi, Niigata, Higashiku, Sapporo, Kobe, Tsukuba, Yokohama
2017-05-25
Active, closed
Pfizer
Phase 3
296
Nagoya, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai, Osaka
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
635
Fukuoka, Kobe, Kyoto, Matsuyama, Nagoya, Osaka, Sapporo, Sendai
2017-04-05
Active, closed
AbbVie
Phase 3
443
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Higashi, Hitachi-shi, Kyoto, Sendai
2017-02-02
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
Kashiwa, Kurume-shi, Sendai, Ōsaka-sayama
2016-06-16
Active, closed
Medtronic Cardiovascular
Not applicable
2,223
Kitakyushu, Sapporo, Tokyo, Kamakura, Sendai, Suita, Fuchū
2016-03
Active, closed
Edwards Lifesciences
Not applicable
1,000
Kitakyushu, Sendai, Suita, Shinjuku, tabashi City
2016-03
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Sapporo, Sendai, Chuo Ku, Fukuoka, Kyoto
2015-11-02
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Sendai, Kure, Sapporo, Shiwa-gun, Kagoshima, Niigata, Shizuoka, Shinjuku-ku
2007-12-06
Rows per page Showing 1–204 of 204
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/sendai

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 204 of those studies with a site in Sendai.

How many clinical trials are recruiting in Sendai?

82 of the 204 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 116 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sendai), 204 studies
PhaseStudiesRecruitingShare
Phase 31164256.9%
Phase 2391919.1%
Phase 1/21466.9%
Observational1155.4%
Not applicable823.9%
Phase 1833.9%
Phase 2/3642.9%
Phase 4211%

Most active sponsors

Lead sponsors with the most studies (Sendai)
Lead sponsorStudiesRecruiting
Pfizer1810
Merck Sharp & Dohme LLC175
AbbVie166
Novartis Pharmaceuticals133
Bristol-Myers Squibb106
Janssen Research & Development, LLC92
AstraZeneca81
Eli Lilly and Company75
Takeda74
Sanofi50
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.